Sign In
Section Navigation
Common TitleVIKING-3
Official Title A Phase III Study to Demonstrate the Antiviral Activity and Safety of Dolutegravir in HIV-1 Infected Adult Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Phase Phase III
ClinicalTrials.gov NCT01328041
Treatments
Dolutegravir
Dolutegravir Tivicay

Dolutegravir

Tradename:TivicayOther Names:DTGClass:Integrase Strand Transfer Inhibitors (INSTI)
Categories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryViiV Healthcare
References
  • Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210:354-62.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.